Gilead bid against it­self in $4.3B deal for CymaBay, fil­ing shows

Gilead Sci­ences was the sole bid­der for liv­er dis­ease biotech CymaBay Ther­a­peu­tics and ul­ti­mate­ly hiked up its ini­tial pro­pos­al by $9.50 per share, ac­cord­ing to a new se­cu­ri­ties fil­ing from Feb. 23.

Like many of the bio­phar­ma ac­qui­si­tions in re­cent mem­o­ry, CymaBay’s pend­ing $4.3 bil­lion ex­it to Gilead was the re­sult of part­ner­ing dis­cus­sions. Be­tween late 2022 and ear­ly this year, CymaBay said it had talked with near­ly two dozen bio­phar­ma­ceu­ti­cal com­pa­nies about po­ten­tial part­ner­ships, per the Fri­day SEC pa­per­work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER